Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.

Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC
J Clin Oncol. 2013 31 (14): 1726-31

PMID: 23569315 · PMCID: PMC3641695 · DOI:10.1200/JCO.2012.44.8027

MeSH Terms (23)

Adult Aged Antibodies, Monoclonal, Humanized Antineoplastic Agents, Hormonal Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms Drug Administration Schedule Female Humans Lapatinib Letrozole Lymphatic Metastasis Middle Aged Neoadjuvant Therapy Neoplasm Staging Nitriles Quinazolines Receptor, ErbB-2 Receptors, Estrogen Trastuzumab Treatment Outcome Triazoles Up-Regulation

Connections (1)

This publication is referenced by other Labnodes entities: